ArticleNature communications2026
FineST: contrastive learning integrates histology and spatial transcriptomics for nuclei-resolved ligand-receptor analysis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Deep Learning-Assisted Prioritization of Candidate Drug Targets in Tumors Using Spatial Multi-Omics.Biology · 2026Review
- Artificial intelligence in oncology: linking biological discovery to clinical utility.Molecular cancer · 2026Review
- CNet-Cox for interpretable network biomarker discovery and survival risk scoring in precise breast cancer prognosis.NPJ digital medicine · 2026Article
- A comprehensive survey of computer vision methods for spatial transcriptomics.Briefings in bioinformatics · 2026Review
- FineST: contrastive learning integrates histology and spatial transcriptomics for nuclei-resolved ligand-receptor analysis.Nature communications · 2026Article
- AINR: attention-guided implicit neural representations for spatial domain identification in spatial transcriptomics.Bioinformatics advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Spatial transcriptomics (ST) has emerged as a powerful tool for analyzing cell-cell communication (CCC) across various biological processes, ranging from embryonic development to cancer progression. However, its limited resolution and high data sparsity hinder the detailed characterization of CCC patterns within complex tissues. Here, we introduce FineST, a deep contrastive learning model that leverages a histology foundation model to fuse ST and histology images, enabling Fine-grained Spatial Transcriptomics analysis. This approach facilitates precise nuclei segmentation, high-resolution RNA expression imputation, and the identification of intricate ligand-receptor interactions. Using both colorectal cancer VisiumHD and breast cancer Xenium datasets, we demonstrate that FineST significantly outperforms existing methods in high-resolution RNA imputation, cell type prediction, and CCC pattern discovery. With focused application to the Visium platform, FineST reveals novel biological insights into tumor-immune interactions across multiple cancer types, including invasive fronts in breast cancer, tertiary lymphoid structures in nasopharyngeal carcinoma, and PD-1 therapy resistance barriers in hepatocellular carcinoma. These findings highlight a new paradigm in ST analysis through the integration of readily available histology images.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.